FGFR2 F276C
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene FGFR2
Variant F276C
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions FGFR2 F276C lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniPort.org). F276C results in increased Fgfr2 expression, altered cellular localization, and ligand-independent Erk phosphorylation in culture (PMID: 30761385).
Associated Drug Resistance
Category Variants Paths

FGFR2 mutant FGFR2 act mut FGFR2 F276C

FGFR2 mutant FGFR2 exon7 FGFR2 F276C

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_000141.5
gDNA chr10:g.121520091A>C
cDNA c.827T>G
Protein p.F276C
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001320658 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_000141 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_001320658.2 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_022970.4 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_001144917.1 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_022970 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_022970.3 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_000141.5 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_001144913 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_001320658.1 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_000141.4 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_001144913.1 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_001144917.2 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_001144913.1 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38
NM_001144917 chr10:g.121520091A>C c.827T>G p.F276C RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 F276C intrahepatic cholangiocarcinoma predicted - sensitive Infigratinib Case Reports/Case Series Actionable In a Phase II trial, Truseltiq (infigratinib) treatment resulted in partial response after 2 months of therapy and response was maintained for 4 months in a patient with advanced intrahepatic cholangiocarcinoma harboring a FGFR2 F276C mutation, which is consistent with inhibition of Erk signaling in cholangiocarcinoma cells expressing FGFR2 F274C in culture (PMID: 30761385; NCT02150967). 30761385
FGFR2 F276C intrahepatic cholangiocarcinoma predicted - sensitive Pazopanib Case Reports/Case Series Actionable In a clinical case study, Votrient (pazopanib) treatment resulted in a partial response that continued for 11 months after starting treatment in a patient with intrahepatic cholangiocarcinoma harboring FGFR2 F276C (PMID: 34480077). 34480077
FGFR2 F276C cholangiocarcinoma predicted - sensitive Pemigatinib Case Reports/Case Series Actionable In a Phase I trial, Pemazyre (pemigatinib) treatment resulted in an objective response rate of 16.7% (2/12, both partial responses) and a disease control rate of 41.7% (5/12) in patients with advanced solid tumors harboring FGFR1/2/3 alterations including amplification, mutation, or fusion, including a partial response in a patient with cholangiocarcinoma harboring FGFR2 F276C (PMID: 37889382; NCT04258527). 37889382